深 滬
undefined undefined
--
NaN.000
NaN.00%
華盛通- 最 高--
- 今 開--
- 振 幅 NaN.00%
- 最 低 --
- 昨 收 --
- 成交額 --
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多What's Going On With Eli Lilly Stock On Tuesday?
Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, with more data expected.
07-30 01:03
强生(JNJ.US)/艾伯维(ABBV.US)遇劲敌！礼来(LLY.US)BTK抑制剂三期临床达主要终点
礼来周二宣布，其经美国食品药品监督管理局批准的布鲁顿酪氨酸激酶抑制剂Jaypirca在针对慢性淋巴细胞白血病或小淋巴细胞淋巴瘤患者的三期头对头临床试验中，达到了主要研究终点。
07-29 21:32
Eli Lilly's Jaypirca Outperforms Imbruvica In Key Leukemia Trial, Showing Strong Response Rates
Eli Lilly and Company (NYSE:LLY) today announced positive topline results from the Phase 3 BRUIN CLL-314 clinical trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine kinase (BTK)
07-29 18:48
AstraZeneca’s Acalabrutinib Study: Real-World Insights for CLL Treatment
AstraZeneca (($AZN)), AstraZeneca plc (($GB:AZN)), AstraZeneca (($DE:ZEGA)), As...
07-29 00:09
BeOne Medicines' Tevimbra gets CHMP endorsement
The European Medicines Agency's Committee for Medicinal Products for Human Use ("CHMP") has issued a positive opinion for BeOne Medicines' Tevimbra (tislelizumab) for use as an neoadjuvant therapy fol...
07-28 21:31
AbbVie’s CLL Study: Enhancing Patient Well-being with Oral Treatments
Abbvie (($ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing ...
07-16 00:08
中金：升亚盛医药-B(06855.HK)目标价至88港元 评级“跑赢行业”
中金发布研报称，考虑到利生妥获批上市及全球适应症拓展前景，维持亚盛医药-B(06855.HK)跑赢行业评级，根据DCF模型，上调目标价27.5%至88港币，较当前股价有15.3%的上行空间。
07-14 10:30
港股早知道 | 两大巨头宣布稀土提价！纳指、标普500指数盘中均创出历史新高
蚂蚁国际否认接入Circle；丘钛科技发盈喜，预期中期综合溢利同比增长约150%-180%；东岳集团预期上半年公司拥有人应占净溢利同比可能大幅增长约150%>>
07-11 07:46
